ERBB2 and breast carcinoma: DESTINY-Breast04 ClinicalTrials found that patients with HER2-low breast cancer have benefited from the antibody-drug conjugates (ADCs) namely trastuzumab deruxtecan, rather than the physician’s choice of chemotherapy,[4] which opened up new therapeutic ideas for HER2-low metastatic breast cancer.